CoChat
Sign Up
Cited by 214Adrenal and Paraganglionic TumorsAdrenal Hormones and DisordersNeuroendocrine Tumor Research Advances

The DOI matches its Crossref record; 155 of the 157 references it cites were found in a registry or an index.

Management of adrenocortical carcinoma

Allolio, Bruno, Hahner, Stefanie, Weismann, Dirk, Fassnacht, Martin·2004·Clinical Endocrinology
DOI 10.1046/j.1365-2265.2003.01881.x
Open this paper in CoChat — free account

Abstract

Adrenocortical carcinoma (ACC) is a rare neoplasm with poor prognosis. Patients present with signs of steroid hormone excess (e.g. Cushing's syndrome, virilization) or an abdominal mass. Tumour size at presentation (mean diameter at diagnosis > 10 cm) is the most important indicator of malignancy. In addition, computed tomography (CT) typically demonstrates an inhomogeneous adrenal lesion with irregular margins and variable enhancement of solid components after intravenous contrast media. Magnetic resonance imaging (MRI) is equally effective as CT and is particularly helpful to visualize invasion into large vessels. Complete tumour removal (R0 resection) offers by far the best chance for long-term survival and therefore surgery is the treatment of choice in stage I-III ACC. Despite tumour resection for cure most patients will eventually develop local recurrence or distant metastases. Thus adjuvant treatment options need to be evaluated in high-risk patients (e.g. radiation therapy of the tumour bed and/or chemotherapy). In tumour recurrence re-operation should always be considered. In metastatic disease (stage IV ACC) not amenable to surgery mitotane (o,p'DDD) remains the first-line therapy. Drug monitoring is needed for effective treatment aiming at concentrations between 14 and 20 mg/l. Patients not responding to mitotane may benefit from cytotoxic chemotherapy (23% partial remissions, 4% complete remissions). Only large prospective multicentre trials comparing different treatment options will allow to make systematic progress in the management of ACC.

Overview

Integrity signals

Registry

Crossref · 10.1046/j.1365-2265.2003.01881.x

Cites

155 of 155 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 157 references

Research works printed but not linked: 12

  1. Bergenstal D., 1959, Regression of adrenal cancer and suppression of adrenal function in men by o, p.‐DDD, Transactions of American Physicians, 72, 341
  2. 10.1210/jc.76.4.1019 · DOI
  3. 10.1210/jc.78.6.1444 · DOI
  4. 10.1210/jc.77.3.852 · DOI
  5. 10.1210/jc.80.3.875 · DOI
  6. MacFarlane D.A., 1958, Cancer of the adrenal cortex: the natural history, prognosis and treatment in the study of 50 cases, Annals of Royal College of Surgery Engl, 109, 613
  7. National Cancer Institute, 1975, DHEW Publishers No (NIH) 75–787 NCI Monograph, 41
  8. 10.1210/jc.79.6.1532 · DOI · Paper page
  9. 10.1210/jc.75.3.826 · DOI
  10. 10.1210/jc.78.3.790 · DOI
  11. 10.1210/jc.80.12.3617 · DOI
  12. Zwermann O., 2003, ACTH inhibits proliferation of adrenal tumors in vivo, Experimental Clinical Endocrinology in Diabetes, 111, V34

Cited by

Sorted by citations

Items 201–214 of 214

Related

See all

Metadata

Authors
Allolio, B., Hahner, S., Weismann, D., & Fassnacht, M.
Affiliations
University of Würzburg (DE)
Corresponding author
Allolio, Bruno
ORCID
Venue
Clinical Endocrinology
Publisher
Wiley
Published
2003-11-24
Volume
60
Issue
3
Pages
273-287
ISSN
  • 0300-0664 (ISSN-L)
  • 1365-2265
DOI
10.1046/j.1365-2265.2003.01881.x
OpenAlex
W2044828697
Cited by
214
References
157
Citations by year
2026: 1 · 2025: 2 · 2024: 2 · 2023: 3 · 2022: 8 · 2021: 7 · 2020: 7 · 2019: 3 · 2018: 8 · 2017: 3 · 2016: 8 · 2015: 8 · 2014: 18 · 2013: 9 · 2012: 8
FWCI
2.49
Type
journal article
Language
en
Open access
closed
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations
  • Clinical Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
  • Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
Keywords
adrenocortical carcinoma, Cushing's syndrome, masculinization, R0 resection, adjuvant radiotherapy, adjuvant chemotherapy, mitotane, drug monitoring, metastatic disease, tumor recurrence, prognosis
MeSH terms
Adrenal Cortex Neoplasms, Antineoplastic Agents, Carcinoma, Humans, Magnetic Resonance Imaging, Neoplasm Staging, Prognosis, Tomography, X-Ray Computed, Cytokines

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review